Avadel Pharmaceuticals plc(AVDL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AVDL Avadel Pharmaceuticals plc

休市中 02-06 16:00:00 EST

21.69

+0.09

+0.42%

盘后21.69

+0.000.00%

16:10 EST

最高21.70	最低21.59	成交量107.70万
今开21.60	昨收21.60	日振幅0.51%
总市值21.29亿	流通市值17.49亿	总股本9,815万
成交额2,332万	换手率1.34%	流通股本8,064万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AVDL","market":"US","secType":"STK","nameCN":"Avadel Pharmaceuticals plc","latestPrice":21.69,"timestamp":1770411600000,"preClose":21.6,"halted":0,"volume":1077043,"hourTrading":{"tag":"盘后","latestPrice":21.69,"preClose":21.69,"latestTime":"16:10 EST","volume":512,"amount":11105.28,"timestamp":1770412204704,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00416666666666666,"floatShares":80642958,"shares":98153471,"eps":-0.002874,"marketStatus":"休市中","change":0.09,"latestTime":"02-06 16:00:00 EST","open":21.6,"high":21.7,"low":21.59,"amount":23317670.761616,"amplitude":0.005093,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.002874,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":1,"adrRate":1,"exchange":"NASDAQ","adjPreClose":21.6,"preHourTrading":{"tag":"盘前","latestPrice":21.63,"preClose":21.6,"latestTime":"09:14 EST","volume":7,"amount":151.659998,"timestamp":1770387276093,"change":0.03,"changeRate":0.001389,"amplitude":0.011574},"postHourTrading":{"tag":"盘后","latestPrice":21.69,"preClose":21.69,"latestTime":"16:10 EST","volume":512,"amount":11105.28,"timestamp":1770412204704,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9708084067071177,"impliedVol":0.307,"impliedVolPercentile":0.1992},"requestUrl":"/m/hq/s/AVDL","defaultTab":"news","newsList":[{"id":"1125822268","title":"爱尔兰高等法院定于2026年2月10日就Avadel针对Alkermes的安排计划举行听证会——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1125822268","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125822268?lang=zh_cn&edition=full","pubTime":"2026-01-20 19:06","pubTimestamp":1768907182,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，爱尔兰高等法院已确定将于2026年2月10日，就Avadel Pharmaceuticals plc针对Alkermes公司所提出的一项安排计划举行听证会。这一关键的法律程序日程，标志着两家制药公司之间一项重要 corporate 行动的推进进入了新的阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"1119129133","title":"Avadel制药宣布股东批准Alkermes收购提案","url":"https://stock-news.laohu8.com/highlight/detail?id=1119129133","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119129133?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:06","pubTimestamp":1768251980,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc（简称：Avadel）宣布，其股东已正式批准由Alkermes公司提出的收购计划。该决议在近日举行的股东特别会议上获得通过，标志着这笔交易迈出关键一步。\n收购提案的通过为两家公司后续整合铺平道路，预计将进一步强化Alkermes在神经科学领域的布局。Avadel旗下核心产品线，特别是针对睡眠障碍的疗法，将与Alkermes现有业务形成协同效应。\n此次股东投票结果也反映出市场对交易前景的认可。分析人士指出，合并后公司有望提升研发效率与市场竞争力，为长期增长注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"1168412976","title":"Avadel Pharmaceuticals宣布完成特发性嗜睡症III期Revitalyz™试验的入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1168412976","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168412976?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:00","pubTimestamp":1766059213,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals宣布完成特发性嗜睡症III期Revitalyz™试验的入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVDL"],"gpt_icon":0},{"id":"1103775048","title":"H Lundbeck a/S：我们对收购Avadel的报价已不再被其董事会视为优越，我们正在考虑我们的选项","url":"https://stock-news.laohu8.com/highlight/detail?id=1103775048","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103775048?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:10","pubTimestamp":1763557811,"startTime":"0","endTime":"0","summary":"H Lundbeck a/S：我们对收购Avadel的报价已不再被其董事会视为优越，我们正在考虑我们的选项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","AVDL","BK4139","BK4007"],"gpt_icon":0},{"id":"1108424260","title":"阿尔凯默斯：拟议交易考虑包括21.00美元现金及一份不可转让的CVR，可能额外支付1.50美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=1108424260","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108424260?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:06","pubTimestamp":1763550362,"startTime":"0","endTime":"0","summary":"阿尔凯默斯：拟议交易考虑包括21.00美元现金及一份不可转让的CVR，可能额外支付1.50美元/股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","ALKS","BK4139","BK4007"],"gpt_icon":0},{"id":"1123510586","title":"阿尔凯默斯：Avadel董事会确认阿尔凯默斯的增值要约中的CVR条款优于Lundbeck提案中的CVR条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1123510586","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123510586?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:03","pubTimestamp":1763550191,"startTime":"0","endTime":"0","summary":"阿尔凯默斯：Avadel董事会确认阿尔凯默斯的增值要约中的CVR条款优于Lundbeck提案中的CVR条款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","AVDL","ALKS"],"gpt_icon":0},{"id":"1118351394","title":"Avadel Pharmaceuticals：根据与阿尔凯默斯的协议，公司与阿尔凯默斯可以在5个工作日内就现有交易进行潜在调整的谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=1118351394","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118351394?lang=zh_cn&edition=full","pubTime":"2025-11-17 18:47","pubTimestamp":1763376431,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals：根据与阿尔凯默斯的协议，公司与阿尔凯默斯可以在5个工作日内就现有交易进行潜在调整的谈判","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4007","ALKS","BK4139"],"gpt_icon":0},{"id":"2583500092","title":"美股异动 | 获两大药企争夺收购 Avadel Pharmaceuticals(AVDL.US)涨超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583500092","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583500092?lang=zh_cn&edition=full","pubTime":"2025-11-15 00:04","pubTimestamp":1763136282,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，美国睡眠药物开发商Avadel Pharmaceuticals(AVDL.US)股价走高，截至发稿，该股涨超20%，报23.215美元。公司周五宣布，丹麦制药商Lundbeck提交了一份未经邀约的收购提案，报价最高达每股23美元，显著高于此前爱尔兰生物科技公司Alkermes(ALKS.US)提出的最高每股20美元要约。尽管市场反应热烈，Avadel表示，公司董事会尚未认定Lundbeck的提案优于现有的Alkermes要约，也未改变对Alkermes收购方案的推荐立场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 获两大药企争夺收购 Avadel Pharmaceuticals(AVDL.US)涨超20%","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"1181941886","title":"Avadel Pharmaceuticals股价在盘前交易中飙升20.6%，因收到Lundbeck的非自愿收购提案","url":"https://stock-news.laohu8.com/highlight/detail?id=1181941886","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181941886?lang=zh_cn&edition=full","pubTime":"2025-11-14 21:25","pubTimestamp":1763126718,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals股价在盘前交易中飙升20.6%，因公司收到了Lundbeck的非自愿提案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"1102688275","title":"Avadel Pharmaceuticals Plc：德意志银行将评级下调至持有，目标价上调至20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102688275","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102688275?lang=zh_cn&edition=full","pubTime":"2025-10-24 19:24","pubTimestamp":1761305069,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals Plc：德意志银行将评级从买入下调至持有，同时将目标价由18美元上调至20美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"1175620420","title":"Avadel Pharmaceuticals Plc：Piper Sandler将评级下调至中性，目标价格从16美元上调至18.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175620420","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175620420?lang=zh_cn&edition=full","pubTime":"2025-10-23 12:25","pubTimestamp":1761193515,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals Plc：Piper Sandler将评级从“增持”下调至“中性”，同时将目标价格由16美元上调至18.5美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"1158775923","title":"Avadel Pharmaceuticals：整合公司运营以推动阿尔凯默斯的成本协同与运营效率","url":"https://stock-news.laohu8.com/highlight/detail?id=1158775923","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158775923?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:03","pubTimestamp":1761131024,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals：整合公司运营以推动阿尔凯默斯的成本协同与运营效率","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS","BK4007","AVDL"],"gpt_icon":0},{"id":"1135866776","title":"Avadel Pharmaceuticals Plc：阿尔凯默斯预计将通过现有现金和新增债务来融资收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1135866776","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135866776?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:03","pubTimestamp":1761130985,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals Plc：阿尔凯默斯预计将通过现有现金和新增债务来融资收购","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ALKS","AVDL"],"gpt_icon":0},{"id":"1128928354","title":"Avadel Pharmaceuticals: 从2028年3月1日起，Lumryz在任何未来FDA批准的适应症销售将适用10%的净销售额特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1128928354","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128928354?lang=zh_cn&edition=full","pubTime":"2025-10-22 18:33","pubTimestamp":1761129198,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals: 从2028年3月1日起，Lumryz在任何未来FDA批准的适应症销售将适用10%的净销售额特许权使用费","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU0109394709.USD","BK4007","IE00BN0W2W23.USD","LU0823416689.USD","IE00BN0W2T93.GBP","LU0889565916.HKD","BK4532","AVDL","LU0320765992.SGD","BK4533","JAZZ"],"gpt_icon":0},{"id":"1119451074","title":"Avadel Pharmaceuticals Plc：根据和解协议的主要条款，Avadel和Jazz将有偏见地撤回各自的诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=1119451074","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119451074?lang=zh_cn&edition=full","pubTime":"2025-10-22 18:31","pubTimestamp":1761129082,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals Plc：根据和解协议的主要条款，Avadel和Jazz将有偏见地撤回各自的诉讼","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVDL"],"gpt_icon":0},{"id":"1153878921","title":"Avadel Pharmaceuticals plc：法院责令Avadel CNS就Lumryz销售向Jazz支付3.85%版税 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1153878921","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153878921?lang=zh_cn&edition=full","pubTime":"2025-09-17 23:51","pubTimestamp":1758124277,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc：法院责令Avadel CNS就Lumryz销售向Jazz支付3.85%版税 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVDL"],"gpt_icon":0},{"id":"1104135411","title":"Avadel Pharmaceuticals plc不同意陪审团对'782专利有效性的裁决","url":"https://stock-news.laohu8.com/highlight/detail?id=1104135411","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104135411?lang=zh_cn&edition=full","pubTime":"2025-09-17 23:51","pubTimestamp":1758124272,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc表示不认同陪审团对'782专利有效性作出的基础裁决。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVDL"],"gpt_icon":0},{"id":"1184289417","title":"Avadel Pharmaceuticals通过获得Xwpharma Ltd独家授权的Valiloxybate加强睡眠医学产品组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1184289417","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184289417?lang=zh_cn&edition=full","pubTime":"2025-09-04 04:32","pubTimestamp":1756931538,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals通过获得来自Xwpharma Ltd的Valiloxybate独家许可，进一步强化其睡眠医学产品组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","BK4007"],"gpt_icon":0},{"id":"1121023340","title":"异动解读 | Avadel Pharmaceuticals盘中大涨26.13%，第二季度每股收益0.1美元超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1121023340","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121023340?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:51","pubTimestamp":1754574719,"startTime":"0","endTime":"0","summary":"制药公司Avadel Pharmaceuticals plc今日盘中股价大涨26.13%，引起投资者广泛关注。这一显著涨幅与公司刚刚发布的强劲季度财报密切相关。根据Avadel Pharmaceuticals plc发布的最新财报显示，公司在第二季度实现了亮眼的业绩表现。报告期内，公司每股收益达到0.1美元，同时税前利润高达649.5万美元。分析人士指出，Avadel Pharmaceuticals的这份优秀财报反映了公司在运营和市场拓展方面取得的显著进展。然而，投资者在做出投资决策时仍需谨慎，密切关注公司后续的业务发展和市场变化。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVDL"],"gpt_icon":0},{"id":"2557561867","title":"Avadel Pharmaceuticals Plc股价飙升15.00% 市值涨1.86亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557561867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557561867?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:33","pubTimestamp":1754573613,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日21时33分，Avadel Pharmaceuticals Plc股票出现波动，股价快速拉升15.00%。截至发稿，该股报12.77美元/股，成交量27.4775万股，换手率0.28%，振幅13.92%。Avadel Pharmaceuticals Plc股票所在的制药行业中，整体跌幅为3.90%。其相关个股中，Emergent Biosolutions Inc.、Ironwood医药、Avadel Pharmaceuticals Plc涨幅较大，Incannex Healthcare Inc.、Akebia Therapeutics, Inc.、大自然药业较为活跃，换手率分别为21.00%、0.74%、0.64%，振幅较大的相关个股有Avadel Pharmaceuticals Plc、Emergent Biosolutions Inc.、Akebia Therapeutics, Inc.，振幅分别为13.92%、10.36%、6.73%。Avadel Pharmaceuticals Plc公司简介：Avadel Pharmaceuticals PLC是一家专业制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807213333a6d8fa6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807213333a6d8fa6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AVDL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avadel.com","stockEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.1605},{"period":"6month","weight":0.7012},{"period":"1year","weight":1.7113},{"period":"ytd","weight":0.0065}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avadel Pharmaceuticals plc于2015年12月1日注册为爱尔兰私人有限公司，并于2016年11月21日重新注册为爱尔兰公共有限公司。Avadel Pharmaceuticals plc是一家专业制药公司，在药物输送方面有很长的历史，专注于发展更安全更有效的配方，解决在研究过程中未满足的医药需求。这家公司专注于：（1）五种功能和专有药物输送平台的发展和许可，（2）发展以药物输送平台为基础的新奇、高价值的产品，（3）收购Eclat药品公司后，美国小众品牌和非专利产品的开发、批准和销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":0.047861},{"month":2,"riseRate":0.5,"avgChangeRate":0.095847},{"month":3,"riseRate":0.448276,"avgChangeRate":-0.017439},{"month":4,"riseRate":0.482759,"avgChangeRate":0.020678},{"month":5,"riseRate":0.517241,"avgChangeRate":-0.004725},{"month":6,"riseRate":0.448276,"avgChangeRate":0.040203},{"month":7,"riseRate":0.4,"avgChangeRate":0.022136},{"month":8,"riseRate":0.433333,"avgChangeRate":0.041512},{"month":9,"riseRate":0.366667,"avgChangeRate":-0.024246},{"month":10,"riseRate":0.4,"avgChangeRate":0.008337},{"month":11,"riseRate":0.533333,"avgChangeRate":0.055436},{"month":12,"riseRate":0.482759,"avgChangeRate":0.035745}],"exchange":"NASDAQ","name":"Avadel Pharmaceuticals plc","nameEN":"Avadel Pharmaceuticals plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avadel Pharmaceuticals plc(AVDL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avadel Pharmaceuticals plc(AVDL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avadel Pharmaceuticals plc,AVDL,Avadel Pharmaceuticals plc股票,Avadel Pharmaceuticals plc股票老虎,Avadel Pharmaceuticals plc股票老虎国际,Avadel Pharmaceuticals plc行情,Avadel Pharmaceuticals plc股票行情,Avadel Pharmaceuticals plc股价,Avadel Pharmaceuticals plc股市,Avadel Pharmaceuticals plc股票价格,Avadel Pharmaceuticals plc股票交易,Avadel Pharmaceuticals plc股票购买,Avadel Pharmaceuticals plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avadel Pharmaceuticals plc(AVDL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avadel Pharmaceuticals plc(AVDL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}